Zacks Investment Research cut shares of HCA Healthcare (NYSE:HCA) from a buy rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “HCA Healthcare’s shares have outperformed the industry in a year’s time. Its top line has been growing over the past several quarters on strong volumes and improved payor and service mix. A number of acquisitions have helped the company gain a strong foothold in the industry. The company has seen the Zacks Consensus Estimate for 2018 earnings being revised upward in the last 60 days. However, it continues to suffer from weak commercial business that has faced declining volumes of admissions over the last few quarters. High level of bad debts and disappointing international business are other headwinds.”
Other research analysts have also recently issued reports about the company. Argus set a $97.00 price objective on HCA Healthcare and gave the company a buy rating in a report on Wednesday, January 10th. Piper Jaffray Companies reissued a hold rating and set a $101.00 price objective on shares of HCA Healthcare in a report on Tuesday, January 30th. Sanford C. Bernstein reissued a market perform rating and set a $116.00 price objective (up from $105.00) on shares of HCA Healthcare in a report on Thursday, February 1st. ValuEngine raised HCA Healthcare from a hold rating to a buy rating in a report on Thursday, November 30th. Finally, BMO Capital Markets lifted their price objective on HCA Healthcare from $96.00 to $115.00 and gave the company an outperform rating in a report on Thursday, February 1st. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $106.05.
HCA Healthcare (HCA) opened at $99.79 on Tuesday. The company has a market capitalization of $35,305.29, a price-to-earnings ratio of 16.80, a P/E/G ratio of 1.01 and a beta of 0.49. HCA Healthcare has a 12-month low of $71.18 and a 12-month high of $106.84. The company has a debt-to-equity ratio of -6.58, a current ratio of 1.62 and a quick ratio of 1.36.
HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Tuesday, January 30th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.25. The company had revenue of $11.56 billion during the quarter, compared to analysts’ expectations of $11.19 billion. HCA Healthcare had a negative return on equity of 49.49% and a net margin of 4.89%. The business’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the business earned $1.80 earnings per share. analysts predict that HCA Healthcare will post 8.71 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Thursday, March 1st will be paid a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, February 28th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.40%. HCA Healthcare’s dividend payout ratio (DPR) is presently 23.57%.
In other news, insider Charles J. Hall sold 119,637 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $100.14, for a total value of $11,980,449.18. Following the completion of the sale, the insider now directly owns 161,181 shares in the company, valued at $16,140,665.34. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Joseph A. Sowell III sold 58,175 shares of the firm’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $95.00, for a total value of $5,526,625.00. Following the completion of the sale, the senior vice president now owns 40,536 shares of the company’s stock, valued at $3,850,920. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 479,918 shares of company stock valued at $48,186,093. 2.90% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. We Are One Seven LLC acquired a new stake in HCA Healthcare in the fourth quarter worth about $110,000. Parallel Advisors LLC increased its position in HCA Healthcare by 76.2% in the fourth quarter. Parallel Advisors LLC now owns 1,337 shares of the company’s stock worth $117,000 after purchasing an additional 578 shares during the period. Salem Investment Counselors Inc. acquired a new stake in HCA Healthcare in the fourth quarter worth about $130,000. Verition Fund Management LLC acquired a new stake in HCA Healthcare in the fourth quarter worth about $205,000. Finally, Bronfman E.L. Rothschild L.P. increased its position in HCA Healthcare by 108.0% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 2,425 shares of the company’s stock worth $213,000 after purchasing an additional 1,259 shares during the period. Hedge funds and other institutional investors own 73.45% of the company’s stock.
HCA Healthcare Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.